Expert perspectives with Neil Shah, MD, PhD, interviewed by Michael Deininger, MD, PhD.

This independent medical education activity features an expert interview with Neil Shah, MD, PhD, focusing on important data from a recent publication in which results of a randomized, phase III study investigating dasatinib once daily as second-line therapy for chronic-phase CML were reported (Shah NP, Kim D-W, Kantarjian H, et al. Haematologica. 2010;95(2):232-240.).    

Dr Shah briefly discusses the rationale for the phase III clinical trial reported in this publication, as well as the effect of dasatinib once daily dosing on efficacy and tolerability.